India, 24th May 2017 – India’s most accredited pharmaceutical wholesaler, GNH India has successfully imported a life-saving medicine called Olaratumab (trade name Lartruvo) that is now available through official import channels.
It is a monoclonal antibody developed by Eli Lilly and Company for the treatment of solid tumors. It is directed against the platelet-derived growth factor receptor alpha. The cost of each injection is approximately Rs. 1,72,500.
Dr Piyush Gupta, Associate Director, GNH India commented, “GNH India has always believed that everyone should have access to proper healthcare and medicines, and we strive to deliver the same to the people irrespective of the global boundaries. In this effort we have aimed to import a rare orphan status drug called, ‘Olaratumab’ that is used to treat soft tissue sarcoma. It gives us tremendous pleasure to be the first Indian specialized wholesaler to provide this life-saving medicine in India and we look forward to many more opportunities”
This drug is classified ‘Orphan drug’ as it is not available easily world-wide. In February 2015, the European Medicines Agency assigned Olaratumab ‘orphan drug’ status for the treatment of soft-tissue sarcoma. The European Commission granted a conditional marketing authorization, based on a Phase II study, valid throughout the European Union on 9 November 2016.
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.
Sign me up for the newsletter!
Notify me of follow-up comments by email.
Notify me of new posts by email.
2014 The Global Indian New Network (TGINN)